IP Library › Granted Patent US 12,444,478
Granted Patent B2
US 12,444,478 · App. 16/758,844 · Granted Oct 14, 2025

Noninvasive molecular clock for fetal development predicts gestational age and preterm delivery

Inventors: Mira N. Moufarrej (Stanford, CA); Thuy T. M. Ngo (Stanford, CA); Joan Camunas-Soler (Stanford, CA); Mads Melbye (Copenhagen, DK); Stephen R. Quake (San Francisco, CA)
Assignees: CZ Biohub SF, LLC; The Board of Trustees of the Leland Stanford Junior University; Statens Serum Institut
G16B20/00C12Q1/6883G16B40/20G16H50/20C12Q1/6876C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,444,478
App. No.
16/758,844
Granted
Oct 14, 2025
Kind
B2
Abstract

The invention is directed to methods of identifying woman is risk for preterm delivery. In some aspects, the methods include quantitating one or more placental or fetal-tissue specific genes in a biological sample from the woman.

Claims (16)

1. A method for treating a pregnant subject for elevated risk of having preterm delivery, comprising:

(a) assaying a maternal sample obtained or derived from the pregnant subject to determine an expression profile of a panel of genes, wherein the panel of genes comprises three or more genes selected from the group consisting of CLCN3, DAPP1, POLE2, PPBP, LYPLAL1, MAP3K7CL, MOB1B, RAB27B, RGS18, and TBC1D15;

(b) computer processing the expression profile determined in (a) (i) against reference expression levels of the panel of genes or (ii) with a trained machine learning model;

(c) determining, based at least in part on the computer processing in (b), that the pregnant subject has an elevated risk of having the preterm delivery; and

(d) administering to the pregnant subject a therapeutic intervention for the elevated risk of having the preterm delivery, wherein the therapeutic intervention is selected from the group consisting of a progesterone, an antibiotic, a cervical cerclage, a cervical pessary, a folate supplement, and an omega-3 fatty acid supplement.

2. The method of claim 1 , wherein the maternal sample is obtained in at least one of months 3 to 8 after pregnancy.

3. The method of claim 1 ,

wherein the reference expression levels are obtained from a first population of subjects having a preterm delivery, a second population of subjects having a full-term delivery, or both.

4. The method of claim 3 , wherein one or more of the reference expression levels are determined using a machine learning technique.

5. The method of claim 1 , wherein the three or more genes comprise RAB27B.

6. The method of claim 1 , wherein the assaying comprises assaying cell-free ribonucleic acid (cfRNA) from the maternal sample obtained or derived from the pregnant subject.

7. The method of claim 1 , wherein the maternal sample is selected from the group consisting of a blood sample, a blood plasma sample, a blood serum sample, and a urine sample.

8. The method of claim 7 , wherein the maternal sample is the blood plasma sample.

9. The method of claim 1 , wherein the assaying comprises performing capture-based enrichment of nucleic acids from the maternal sample for the panel of genes.

10. The method of claim 9 , wherein the capture-based enrichment comprises use of primers or probes configured to specifically hybridize to nucleic acid sequences of the panel of genes.

11. The method of claim 1 , wherein (b) further comprises determining that the expression profile indicates elevated expression of PPBP in the pregnant subject having the elevated risk of having the preterm delivery.

Continuity (3)
Provisional Application 62578360 · Oct 27, 2017
Provisional Application 62576033 · Oct 23, 2017
Related Publication 20230140653A1 · May 4, 2023
References Cited (26)
US 20150366835A1 · Pogue-Geile · 2015 [cited by examiner]
JP 2011522272 · 2011 [cited by applicant]
JP 2015511122 · 2015 [cited by applicant]
WO 2009134452A2 · 2009 [cited by applicant]
WO WO2014105985A1 · 2014 [cited by examiner]
WO 2015010442A1 · 2015 [cited by applicant]
WO 2017096405A1 · 2017 [cited by applicant]
Linda K. Woolery, Jerzy Grzymala-Busse, Machine Learning for an Expert System to Predict Preterm Birth Risk, Journal of the American Medical Informatics Association, vol. 1, Issue 6, Nov. 1994, pp. 439-446, https://doi.… [cited by examiner]
Lan Yang et al. Maternal-Fetal Medicine Obstetrics & Gynecology Science 2015; 58(4): 261-267. Published online: Jul. 16, 2015 (Year: 2015). [cited by examiner]
Spencer, K., Cowans, N.J. and Stamatopoulou, A. (2008), ADAM12s in maternal serum as a potential marker of pre-eclampsia. Prenat. Diagn., 28: 212-216. https://doi.org/10.1002/pd.1957 (Year: 2008). [cited by examiner]
Emma L. Davies, Jacqueline S. Bell & Sohinee Bhattacharya (2016) Preeclampsia and preterm delivery: A population-based case-control study, Hypertension in Pregnancy, 35:4, 510-519, DOI: 10.1080/10641955.2016.1190846 (Ye… [cited by examiner]
Hendrix et al. (“An immunohistochemical analysis of Rab27B distribution in fetal and adult tissue”, Int. J. Dev. Biol. 56: 363-368 (2012) https://doi.org/10.1387/ijdb.120008ah). (Year: 2012). [cited by examiner]
Neofytou et al. (“Targeted capture enrichment assay for non-invasive prenatal testing of large and small size sub-chromosomal deletions and duplications.” PLoS One. Feb. 3, 2017;12(2):e0171319. doi: 10.1371) (Year: 2017… [cited by examiner]
Khurram et al.(Human myometrial adaptation to pregnancy: cDNA microarray gene expression profiling of myometrium from non-pregnant and pregnant women, Molecular Human Reproduction, vol. 9, Issue 11, Nov. 2003, pp. 681-7… [cited by examiner]
Conde-Agudelo, et al., “Novel biomarkers for the prediction of the spontaneous preterm birth phenotype: a systematic review and meta-analysis”, BJOG: An International Journal of Obstetrics & Gynaecology, Mar. 15, 2011, … [cited by applicant]
Ngo, et al., “A Noninvasive Molecular Clock for Fetal Development Predicts Gestational Age and Preterm Delivery”, bioRxiv, Bioengineering, 2007, p. 212910-212914. [cited by applicant]
Siler-Khodr, et al., “Gonadotropin-releasing Hormone Effects on Placental Hormones during Gestation: I. Alpha-Human Chorionic Gonadotropin, Human Chorionic Gonadotropin and Human Chorionic Somatomammotropin”, Biology of… [cited by applicant]
Westergaard, et al., “Single Measurements ofChorionic Gonadotropin and Schwangerschafts Protein for Assessing Gestational Age and Predicting the Day of Delivery”, The Journal of Reproductive Medicine, 1985, vol. 30, No.… [cited by applicant]
Application PCT/US2018/057142, International Search Report and Written Opinion. May 2, 2019, 19 pages. [cited by applicant]
EP18871519.7, “Extended European Search Report”, Oct. 15, 2021, 19 pages. [cited by applicant]
PCT/US2018/057142, “International Preliminary Report on Patentability”, May 7, 2020, 13 pages. [cited by applicant]
EP18871519.7 , “Partial Supplementary European Search Report”, Jul. 14, 2021, 22 pages. [cited by applicant]
Fiddes et al., “Isolation, Cloning and Sequence Analysis of the cDNA for the Alpha-Subunit of Human Chorionic Gonadotropin”, Nature. vol. 281, No. 5730 Available online at: https://www.ncbi.nlm.nih.gov/pubmed/?term=Natu… [cited by applicant]
Fiddes et al., “The Gene Encoding the Common Alpha Subunit of the Four Human Glycoprotein Hormones”, Journal of Molecular and Applied Genetics. vol. 1, No. 1 Available online at: https://www.ncbi.nlm.nih.gov/pubmed/?ter… [cited by applicant]
Heng et al., “Maternal Whole Blood Gene Expression at 18 and 28 Weeks of Gestation Associated with Spontaneous Preterm Birth in Asymptomatic Women”, PLOS One, vol. 11, No. 6, Jun. 22, 2016, 17 pages. [cited by applicant]
Heng et al., “Whole Blood Gene Expression Profile Associated with Spontaneous Preterm Birth in Women with Threatened Preterm Labor”, PLOS One, vol. 9, No. 5, May 14, 2014, pp. 1-13. [cited by applicant]